27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Among 91,881 participants (mean age 59.3 at baseline, 55.0% female participants), 16,507 incident ADRD cases were identified from Medicare claims (1999-2016, mean follow-up 9.3 years). 5 key findings →
Design: cohort study Participants: 91,881 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Of 19 114 randomized participants, 16 855 (88.2%) had longitudinal gait and cognitive data for inclusion in this study (mean [SD] age, 75.0 [4.4] years; 9435 women [56.0%], 7558 participants [44.8%] with 12 or more years of education). 5 key findings →
Design: cohort study Participants: 7,558 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
An estimated 8.8 million Indians older than 60 years have dementia. 2 key findings →
Design: longitudinal study Participants: 2,528 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
1,901 participants completed the MoCA and 547 the HCAP. 5 key findings →
Design: cohort study Participants: 1,901 Evidence: moderate
Full summary, score breakdown and related studies → Original source
receipt of (1) any mental health treatment (medication or psychotherapy); (2) any psychotherapy in a calendar quarter. 5 key findings →
Design: cohort study Participants: 1,913,945 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among these, 85.5% were non-Hispanic (NH) white, 8% NH black, 4.34% Hispanic or Latino, 1.6% NH Asian or Pacific Islander, and 0.3% NH American Indian or Alaska Native adults. 5 key findings →
Design: retrospective cohort Participants: 10,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. 3 key findings →
Design: cohort study Participants: 7,540 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The sample included 673,102 PWD (mean age 86, 66% female, 85% White, 7.3% Black, 6.3% Hispanic, 1.6% AAPI) enrolled in 4371 hospices nationwide. 5 key findings →
Design: cohort study Participants: 673,102 Evidence: moderate
Full summary, score breakdown and related studies → Original source
12,887 participants were interviewed at baseline. 11,718 were free of dementia, of whom 8137 (69%) were reinterviewed, contributing 34,718 person-years of follow-up. 3 key findings →
Design: cohort study Participants: 12,887 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this study, risk of dementia significantly increased after ischemic stroke, independent of vascular risk factors. 5 key findings →
Design: prospective cohort Participants: 379 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Late-life declines in blood pressure following prolonged hypertension may be associated with poor cognitive outcomes. 5 key findings →
Design: cohort study Participants: 833 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This is the first report of incidence rate differences for dementia and AD in studies of 2 populations from nonindustrialized and industrialized countries using identical methods and the same group of investigators in both sites. 2 key findings →
Design: longitudinal study Participants: 2,459 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among those newly diagnosed, Black and Hispanic patients encountered higher total costs compared to White patients, and ADRD patients living in the most vulnerable areas experienced the highest total costs compared to patients living in other regions. 5 key findings →
Design: longitudinal study Participants: 742,175 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia diagnosis recording in general hospitals is increasing but remains less likely in some groups. 1 key finding →
Design: cohort study Participants: 21,387 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Compared with no sensory impairment, DSI was associated with increased risk of all-cause dementia (hazard ratio [HR], 2.60; 95% CI, 1.66-2.06; P Conclusions and relevance In this cohort study, DSI was associated with increased risk of dementia, particularly AD. 5 key findings →
Design: cohort study Participants: 5,888 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among subjects identified as having dementia by the prediction model, 43.5% to 50.2%, depending on the survey year, reported that they were informed of the dementia status by their physician. 5 key findings →
Design: cohort study Participants: 8,686 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Generally, Blacks and Latinos reported higher prevalence of poor HRQOL compared with whites. 5 key findings →
Design: cohort study Participants: 10,886 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The analytic cohort included 2488 black and white older adults with repeated depressive symptom assessments from baseline to year 5 who were free of dementia throughout that period. 4 key findings →
Design: prospective cohort Participants: 1,322 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Black decedents were less likely than White decedents to use hospice for 3 or more days (132 of 378 [34.9%] vs 385 of 834 [46.2%]; P Conclusions and relevance Despite the increase in the use of hospice care in recent decades, racial disparities in the use of hospice remain, especially for noncancer deaths. 1 key finding →
Design: cohort study Participants: 1,212 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this community-based cohort without dementia, florbetapir uptake is associated with older age and APOE genotype. 5 key findings →
Design: longitudinal study Participants: 329 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MCI prevalence varied among Hispanic/Latino backgrounds, but not as widely as reported in the previous studies. 5 key findings →
Design: cohort study Participants: 6,377 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among the 1 637 484 Veterans Health Administration patients, the mean (SD) age was 68.6 (7.7) years, and 1 604 677 (98.0%) were men. 5 key findings →
Design: cohort study Participants: 7,318 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The cohort sample included 5058 beneficiaries with dementia (mean [SD] age, 85.5 [8.0] years; 3038 women [60.1%]; 809 [16.0%] non-Hispanic Black, 357 [7.1%] Hispanic, and 3892 non-Hispanic White respondents [76.9%]). 4 key findings →
Design: cohort study Participants: 5,058 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Antipsychotic initiation and use were common during hospitalization, most often for delirium, and individuals were frequently discharged on these medications. 3 key findings →
Design: cohort study Participants: 17,775 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These analyses give a population based estimated median survival for incident dementia of 4.5 years. 2 key findings →
Design: cohort study Participants: 438 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →